Author + information
- Aslı Azakoğlu Karaca1,
- Sami Sabri Bulgurlu1,
- Akın Dayan1,
- Özlem Tanrıöver2,
- Gürkan Karaca3 and
- Refik Demirtunç4
8–14 million people world wide are die due to diabetes, cardiovascular diseases, cancer and many other chronic diseases. Also rapid change of lifestyle, environmental conditions and due to stress factors prevalence especially of type 2 diabetes mellitus (diabetes) increased in developing countries. As it is known diabetic patients CVD (Cardiovascular Disease) risk are 2-4 times higher than non-diabetic individuals. In addition, DM is an important cardiovascular risk factor, and facilitates the development of atherosclerosis by several mechanisms. Guidelines for diabetes treatment recommend the routine use of aspirin in patients with diabetes mellitus (DM) who have cardiovascular disease (CVD), those with at least one CVD risk factor, and for anyone with DM who is >30 years of age or, if contraindicated, an alternative antiplatelet agent. The aim of this study is; to evaluate the frequency of ASA (Asetil salisilic asid) use in type 2 Diabetic patients with dyslipidemia, and to examine the relationship between patients demographic data such as (gender, blood pressure, body mass index, smoking&alcohol use) and their concominant disease like CVD (Cardiovascular Disease), HT (Hypertension), CRF (Chronic renal failure), SVD (Serebrovascular Disease)…ext.
Materials and methods
In this observational study, we have included 910 type 2 diabetic and dislipidemic patients 25–87 years of age, who had at least one visit to our diabetes and internal medicine outpatient clinic in the following periods: January 2012-November 2012. Aspirin use was asked to patients and then patient-records were analysed for obtaining the other data.
Of the participants, 35.8% (n=326) were males and 64.2% (n=584) were females. The mean age was 57.27 ± 10.00. Of the participants, 26.8% (n=244) had coronary artery disease, 62.3% (n=567) had hypertension, 5.2% (n=47), had cerebrovascular disease, 14.6% patients (n=133) had retinopathy and 6.2% (n=56) had thyroid disease. Our analysis has shown that ASA, as an antiplatelet agent were prescribed to 38,6% of the type 2 diabetic and dislipidemic patients and 61,4% of the patients were not using ASA. There was a statistically significant difference between genders in terms of current ASA use. Men were more likely to use ASA (43.3%), compared to women (36%) (p <0.05). 10.2% (n=93) of the patients, had stopped using ASA. When we examined all the cases of patients, 5.7% (n=52) stopped using aspirin for medical reasons, 4.5% (n=41) left for other reasons.
Patients with type 2 diabetes and dislipidemia whose Framingham risk scores (estimated 10-year Global CVD Risk) are high should be treated based on the ATP-III (2004), CCS(2009), ESC (2007) guidelines. Despite the ADA guidelines they are not always under antiplatelet treatment, especially for primary prevention. We found significant underuse of aspirin therapy among our study population. For the prevention of diabetes complications, efforts towards increasing these rates of antiplatelet prophylaxis are necessary.